New hope for advanced colon cancer: experimental drug combo enters final testing phase
NCT ID NCT07549412
First seen Apr 30, 2026 · Last updated Apr 30, 2026
Summary
This phase 3 study tests an experimental drug called precemtabart tocentecan, given alone or with bevacizumab, against a standard treatment for people with metastatic colorectal cancer that has progressed after prior therapies. About 1,020 participants will be enrolled to see if the new drug helps them live longer. The goal is to offer a better option for those who have run out of effective treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Please Contact U.S. Medical Information
Rockland, Massachusetts, 02370, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Please Contact the Communication Center
Darmstadt, 64293, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.